Invented by David J. Livingston, Andrew Carr, Philippe Fernandes, Metrobiotech LLC, Metro International Biotech LLC
Nicotinamide Mononucleotide (NMN) is a compound that has gained significant attention in recent years due to its potential anti-aging properties. As a precursor to nicotinamide adenine dinucleotide (NAD+), NMN has been studied for its ability to enhance cellular energy production and improve overall health and longevity. With the growing interest in NMN, the market for its crystal forms has also seen a surge in demand.
Crystal forms of NMN refer to the different physical structures in which the compound can exist. These crystal forms are important as they can affect the stability, solubility, and bioavailability of NMN, ultimately influencing its effectiveness as a supplement or pharmaceutical product. The market for crystal forms of NMN is driven by the need for high-quality, stable, and easily absorbable forms of the compound.
One of the key factors driving the market for crystal forms of NMN is the increasing demand for anti-aging and longevity products. As people become more conscious of their health and seek ways to slow down the aging process, NMN has emerged as a promising solution. Crystal forms of NMN that offer enhanced stability and bioavailability are highly sought after by consumers looking to incorporate NMN into their wellness routines.
Furthermore, the market for crystal forms of NMN is also driven by the growing interest from the pharmaceutical industry. NMN has shown potential in various preclinical studies for its ability to improve metabolic health, enhance mitochondrial function, and protect against age-related diseases. Pharmaceutical companies are exploring the development of NMN-based drugs, and the availability of different crystal forms allows them to optimize the formulation and delivery of these drugs.
In addition to the demand from the anti-aging and pharmaceutical sectors, the market for crystal forms of NMN is also influenced by the research community. Scientists and researchers studying NMN require high-quality crystal forms to conduct their experiments and investigations. The availability of different crystal forms allows researchers to explore the compound’s properties and potential applications in a more comprehensive manner.
However, it is important to note that the market for crystal forms of NMN is still relatively niche and evolving. The production and commercial availability of these crystal forms are limited compared to other more established supplements or pharmaceutical compounds. As a result, the market is currently dominated by a few key players who have invested in research and development to produce high-quality crystal forms of NMN.
In conclusion, the market for crystal forms of NMN is growing in response to the increasing demand for anti-aging and longevity products, as well as the interest from the pharmaceutical industry and research community. As the understanding of NMN’s potential benefits continues to expand, the market for crystal forms of NMN is likely to witness further growth and innovation.
The Metrobiotech LLC, Metro International Biotech LLC invention works as follows
The invention is directed to crystalline mononucleotides of a? -nicotinamide, their methods of preparation and pharmaceutical preparations related thereto. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.
Background for Crystal Forms of?-nicotinamide Mononucleotide
?-Nicotinamide Mononucleotide(NMN) has recently gained attention for its use as a treatment, amelioration or mitigation, slowing down, arresting, preventing and/or reversing age-associated degenerative change, such as age related obesity, age related increases in blood lipids, age associated decreases of insulin sensitivity and age associated decreases in memory.
There is a requirement for improved NMN compositions, given the therapeutic benefits of this compound. There is also a need to improve the methods of preparing and formulating mononucleotide?-nicotinamide.
One aspect of this invention is a crystalline substance having the formula (I)
Another aspect” of the invention is the methods of preparing crystalline compounds with formula (I).
In certain embodiments of the invention, a pharmaceutical composition suitable for human patients is provided. It comprises a crystalline substance of formula (I) and one or more pharmaceutically accepted excipients. In certain embodiments the pharmaceutical preparations can be used to treat or prevent a condition or illness as described in this document. The pharmaceutical preparations in certain embodiments are low enough in pyrogen activity for intravenous administration to a patient.
FIG. “FIG.
FIG. “FIG.
FIG. “FIG.
FIG. The 1H NMR spectrum of NMN after drying is shown in Figure 4. “As shown in the spectra of Form 1, Form 2 contains about 1.1-1.2 DMSO molecule per molecule NMN.
FIG. “FIG.
FIG. “FIG.
FIG. The mass plot of amorphous NmN shows the dynamic change in vapor sorption. When amorphous NMN samples are exposed to atmospheric moisture, they go through phases. FIG. FIGURE 7 shows mass change with time. The amorphous material is hygroscopic, until it starts to crystallize. Weight loss below 1000 minutes indicates a crystallisation. The material is still crystalline after the double cycle and retains the same XRPD patterns. However, it can still pick up mass (up to 9 w/w changes).
FIG. “FIG.
In certain embodiments of the invention, a compound crystalline with the formula (I) is provided.
In certain embodiments, an amorphous crystalline compound (I) does not contain molecules of solvent (e.g. the crystal lattice is free of such molecules). In certain embodiments the crystalline compound (I) of formula is anhydrous or substantially anhydrous. In alternative embodiments, the crystalline compound (I) can be solvated. In some embodiments, a crystalline compound (I) of formula is a dimethylsulfoxide solvate (DMSO).
Any crystalline compounds described herein can be used to manufacture a drug for treating any disease or condition disclosed herein.
In certain embodiments, compounds of the invention can be assembled into more than one crystalline formation. In one exemplary embodiment, a crystalline compound with the formula (I), exists in ‘form I’. Below, we will describe in detail?form I? and?form 2?. Polymorphs are the different forms. herein.
In certain embodiments the powder X-ray diffractogram (XRD) is used to characterize the polymorph. 0 is the diffraction angles, measured in degree. In certain embodiments the diffractometer is used to measure the diffraction angles as twice the diffraction?. In certain embodiments, diffraction patterns are described in terms of X-ray intensities measured against angle?.
In certain embodiments an anhydrous crystal compound of formula I has two values: 20.03, 20.14, 21.83 and 25.73. Values 20.03, 20.14, 21.83 and 25.73. Further embodiments of the anhydrous crystal compound have 2? Values 20.03, 20.14, 21.03, 21.83, 23.08 ; 23.39 ; 25.73 ; and 26.59. In further embodiments, anhydrous crystalline compound has two? Values 7.70, 11.54, 12.64; 16.99; 18.03; 20.03 ; 20.14 ; 20.83 ; 21.03 ; 21.83 ; 23.08 ; 23.39 ; 25.48 ; 25.73 ; 26.59 ; and 29.78. In yet another embodiment, the anhydrous crystal compound has two? “7.70, 9.95, 11.54; 12.99; 16.03; 18.99; 1916; 19.44 ; 20.03 ; 20.14 ; 20.83 ; 21.03 ; 21.83 ; 22.44 ; 23.08 ; 23.39 ; 23.89 ; 24.08 ; 24.53 ; 24.68 ; 25.05 ; 25.48 ; 25.73 ; 26.08 ; 26.59 ; 27
Click here to view the patent on Google Patents.
Leave a Reply